CD274 and vitiligo: Patients with melanoma receiving PD-1/PD-L1 inhibitors have demonstrated an increased incidence of VLD, ranging from 2% to 25%, which is considerably higher than the prevalence of vitiligo in the general population (estimated globally at 0.5% to 1%) (10).